睿知中国医院研究地图
候选清单

广州

广东省人民医院

Guangdong Provincial People's Hospital

在本站收录的 53 种疾病中,这家医院列在其中 24 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

广东省人民医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma14 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma19 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma54 篇牵头论文牵头 1 项开放试验
  4. 胃癌Stomach cancer21 篇牵头论文牵头 1 项开放试验
  5. 肝母细胞瘤Hepatoblastoma1 篇牵头论文
  6. 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
  7. 脊索瘤Chordoma1 篇牵头论文
  8. 骨肉瘤Osteosarcoma11 篇牵头论文
  9. 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
  10. 神经母细胞瘤Neuroblastoma0 篇牵头论文
  11. 多发性骨髓瘤Multiple myeloma3 篇牵头论文
  12. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia1 篇牵头论文
  13. β 地中海贫血Beta thalassaemia1 篇牵头论文
  14. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder3 篇牵头论文
  15. IgG4相关性疾病IgG4-related disease3 篇牵头论文
  16. 重症肌无力Myasthenia gravis1 篇牵头论文
  17. 大动脉炎Takayasu arteritis0 篇牵头论文
  18. 特发性肺纤维化Idiopathic pulmonary fibrosis2 篇牵头论文
  19. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
  20. 法布雷病Fabry disease1 篇牵头论文
  21. 白塞病Behçet disease1 篇牵头论文
  22. IgA 肾病IgA nephropathy8 篇牵头论文牵头 1 项开放试验
  23. 原发性胆汁性胆管炎Primary biliary cholangitis4 篇牵头论文
  24. 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文

未列出的收录疾病:尤文肉瘤、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 14 篇,占 0.6%。

牵头论文
14
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 4420232024: 1120242025: 772025

广州有 23 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
    分期
    II期
    开始
    2025-06
    登记号
    NCT07070479

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心中山、广州、珠海、长沙

  2. 正在招募
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    分期
    不分期
    开始
    2023-06
    登记号
    NCT05892354

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:广西医科大学第一附属医院;另有 13 家列出的医院为研究中心南宁、南昌、广州、杭州、柳州、桂林、梧州、海口、福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题放疗技术影像与人工智能诱导/同步化疗
论文中的科室耳鼻喉/头颈外科肿瘤内科放疗科影像/核医学科
牵头的论文14
  1. Chemoimmunotherapy as induction treatment in concurrent chemoradiotherapy for patients with nasopharyngeal carcinoma stage IVa.2025Annals of medicine免费全文
  2. Integrating pan-immune-inflammation value into personalized survival prediction of nasopharyngeal carcinoma: a large-scale long-term retrospective study.2025BMC cancer免费全文
  3. Efficacy and safety of induction immunotherapy plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.2025British journal of cancer免费全文
  4. Prediction of Recurrence using a Stacked Denoising Autoencoder and Multifaceted Feature Analysis of Pretreatment MRI in Patients with Nasopharyngeal Carcinoma.2025Current radiopharmaceuticals
  5. Cholesterol-to-lymphocyte ratio (CLR)-based nomogram as a prognostic tool in nasopharyngeal carcinoma: a large-scale long-term retrospective study.2025European journal of medical research免费全文
  6. Application of Large Language Models in TN Staging and Treatment Response Evaluation for Patients With Nasopharyngeal Carcinoma: A Comparative Performance Analysis of ChatGPT-4o-Latest and DeepSeek-V3-0324.2025Journal of magnetic resonance imaging : JMRI
  7. Key Risk Factors for Postoperative Hypotension in Nasopharyngeal Carcinoma Patients After Endoscopic Surgery: A Retrospective Study.2025Medical science monitor : international medical journal of experimental and clinical research免费全文
  8. ThermomiR-377-3p-induced suppression of Cirbp expression is required for effective elimination of cancer cells and cancer stem-like cells by hyperthermia.2024Journal of experimental & clinical cancer research : CR免费全文
  9. Enhancer remodeling activates NOTCH3 signaling to confer chemoresistance in advanced nasopharyngeal carcinoma.2023Cell death & disease免费全文
  10. A glutathione-sensitive cationic polymer delivery of CRISPR-Cas9 RNA plasmid for targeting nasopharyngeal carcinoma gene therapy.2023Colloids and surfaces. B, Biointerfaces
  11. Endoscopic surgery versus intensity-modulated radiotherapy in locally advanced recurrent nasopharyngeal carcinoma: a multicenter, case-matched comparison.2023Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale免费全文
  12. Using the non-distortion IVIM to reduce the need for contrast agents in nasopharyngeal MRI.2023Magnetic resonance imaging
  13. Effects of combination docetaxel with NO treatment to enhance the anti-nasopharyngeal carcinoma efficiency in vitro and in vivo.2022European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  14. Long-Term Outcomes of Cochlear Implantation in Irradiated Ears of Nasopharyngeal Carcinoma Patients.2021The Laryngoscope
中文论文(未计入)1
  1. [Skull base defect reconstruction after surgery for recurrent nasopharyngeal carcinoma].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Early Nutritional Intervention in NPC Patients Undergoing Concurrent Chemoradiotherapy状态不明NCT04810936牵头方不分期2019-07 启动
  2. Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial正在招募NCT07070479研究中心II期2025-06 启动
  3. Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy正在招募NCT05892354研究中心不分期2023-06 启动
  4. Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images状态不明NCT05202626研究中心2021-12 启动
  5. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)已完成NCT03924986研究中心III期2019-03 启动
PubMed 以外找到的论文(未计入)10
  1. 1376P A comprehensive overview of immune-related adverse events induced by immune checkpoint inhibitors in nasopharyngeal carcinoma2025Annals of Oncology论文
  2. Efficacy and safety of induction chemoimmunotherapy versus induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A meta-analysis.2025Journal of Clinical Oncology论文
  3. 402O Preliminary results of phase II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)2024Annals of Oncology论文
  4. 455P A real-world study: Induction chemoimmunotherapy versus induction chemotherapy followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma patients with stage IVa2024Annals of Oncology论文
  5. Microplastics Antagonize the Therapeutic Effect of Curcumin on Nasopharyngeal Carcinoma Through Inhibiting the Apoptosis Pathway2024SSRN Electronic Journal预印本
  6. SICNet: Learning selective inter-slice context via Mask-Guided Self-knowledge distillation for NPC segmentation2024Journal of Visual Communication and Image Representation论文
  7. Enhanced Multi-Task Nasopharyngeal Carcinoma Recurrence Prediction by Knowledge Distillation with Loss-Balanced Weighting Strategy2023International Conference on Intelligent Computing and Human-Computer Interaction (ICHCI)会议论文
  8. Risk Factors Analysis of Post Anesthesia Induction Hypotension in Patients with Recurrent Nasopharyngeal Carcinoma2023Journal of medicine and health science.论文
  9. Additional file 1 of Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis2022Figshare综述
  10. Effect of Exercise on Sternoceleidomastoid Muscular Fibrosis after Radiotherapy for Nasopharyngeal Carcinoma Patients Analyzed by Shear-Wave Elastography2022Rehabilitation Medicine论文

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 19 篇,占 0.7%。

牵头论文
19
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 5520222023: 5520232024: 4420242025: 552025

广州有 11 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题免疫治疗新辅助与综合治疗分子标志物与基因
论文中的科室肿瘤内科放疗科影像/核医学科
牵头的论文19
  1. Association Between Treatment-Related Adverse Event Trajectory and Prognosis in Esophageal Cancer Receiving Neoadjuvant Immunochemotherapy.2025Annals of surgical oncology
  2. ISCU-p53 axis orchestrates macrophage polarization to dictate immunotherapy response in esophageal squamous cell carcinoma.2025Cell death & disease免费全文
  3. m6A-mediated circG3BP1 translocation to stress granules promotes nucleation and senescence-linked chemoresistance.2025Cell reports
  4. The mechanism of high mobility group box-1 in the proliferation and macrophage polarization in esophageal squamous cell carcinoma cells.2025European journal of medical research免费全文
  5. Co-Infection by Porphyromonas gingivalis and Fusobacterium nucleatum Increases PD-L1 Expression in Esophageal Cancer Tissues.2025MicrobiologyOpen免费全文
  6. Decoding tumor stage by peritumoral and intratumoral radiomics in resectable esophageal squamous cell carcinoma.2024Abdominal radiology (New York)免费全文
  7. ASO Author Reflections: Enhancing Treatment Outcomes in Unresectable Esophageal Squamous Cell Carcinoma Through Immunochemotherapy.2024Annals of surgical oncology
  8. Induction Immunochemotherapy Yields a Higher Conversion Rate and Better Overall Survival than Chemotherapy in Initially Unresectable Esophageal Squamous Cell Carcinoma.2024Annals of surgical oncology
  9. Lymphatic endothelial cell-mediated accumulation of CD177+Treg cells suppresses antitumor immunity in human esophageal squamous cell carcinoma.2024Oncoimmunology免费全文
  10. Early and Persistent Dysphagia Relief Predicts Tumor Response in Esophageal Squamous Cell Carcinoma Patients Treated with Immunochemotherapy.2023Annals of surgical oncology
  11. PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma.2023Cancer immunology, immunotherapy : CII免费全文
  12. Dissecting T-cell heterogeneity in esophageal squamous cell carcinoma reveals the potential role of LAIR2 in antitumor immunity.2023Clinical and experimental immunology
  13. Evidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma.2023JAMA oncology
  14. COL19A1 is a predictive biomarker for the responsiveness of esophageal squamous cell carcinoma patients to immune checkpoint therapy.2023Thoracic cancer免费全文
  15. Comment on: "Is Adjuvant Therapy a Better Option for Esophageal Squamous Cell Carcinoma Patients Treated With Esophagectomy? A Prognosis Prediction Model Based on Multicenter Real-world Data".2022Annals of surgery
  16. Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma Using Routine Computed Tomography Imaging: Comparison of Size-Based Measurements and Radiomics-Based Models.2022Annals of surgical oncology
  17. Predictive value of the presence of Prevotella and the ratio of Porphyromonas gingivalis to Prevotella in saliva for esophageal squamous cell carcinoma.2022Frontiers in cellular and infection microbiology免费全文
  18. Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro).2022Frontiers in immunology免费全文
  19. Assessment of durable chemoimmunotherapy response via circulating tumor DNA in advanced esophageal squamous cell carcinoma.2022Thoracic cancer免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.状态不明NCT05900583牵头方2023-06 启动
  2. Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC.状态不明NCT06125262牵头方2022-11 启动
  3. The PET-CT Predicting Response to Immunochemotherapy in Esophageal Cancer状态不明NCT05615103牵头方2022-11 启动
  4. Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients状态不明NCT05596890牵头方II期2022-11 启动
  5. Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting已完成NCT05615129牵头方2021-10 启动
  6. A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors已完成NCT06549816研究中心I期2024-08 启动
  7. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
PubMed 以外找到的论文(未计入)19
  1. Alternative dosing regimens of tislelizumab proposed using modeling and simulation.2025Journal of Clinical Oncology会议摘要
  2. 418P A PET/CT image-based deep learning approach for precise survival prognosis and clinical management of treatments in patients with esophageal carcinoma2024Annals of Oncology论文
  3. 593. DEEP LEARNING-BASED PROGNOSTIC MODEL INTEGRATING TUMOR-INFILTRATING LYMPHOCYTES FOR ESOPHAGEAL CANCER: A MULTICENTER RETROSPECTIVE COHORT STUDY2024Diseases of the Esophagus论文
  4. MO57-3 Effect of immunochemotherapy time-of-day infusion, sequence and interval on prognosis of advanced esophageal cancer2024Annals of Oncology论文
  5. 367. SPATIAL ORGANIZATION OF TUMOR-INFILTRATING LYMPHOCYTES PREDICTS PROGNOSIS OF PATIENTS WITH ESOPHAGEAL CANCER RECEIVING IMMUNOTHERAPY—A DEEP-LEARNING APPROACH2023Diseases of the Esophagus论文
  6. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figshare数据集
  7. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  8. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  9. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  10. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  11. Comparison of efficacy and safety of neoadjuvant regimens for resectable esophageal squamous cell carcinoma: A meta-analysis.2023Journal of Clinical Oncology会议摘要
  12. Identification of secretory factors associated with suppressive tumor microenvironment in esophageal cancer2023Research Square预印本
  13. Induction immunochemotherapy conversion rate and survival outcomes versus chemotherapy in initially unresectable esophageal squamous cell carcinoma.2023Journal of Clinical Oncology会议摘要
  14. Influence of high COL19A1 expression on the effectiveness of neoadjuvant immunotherapy plus chemotherapy and long-term survival in patients with esophageal squamous cell carcinoma.2023Journal of Clinical Oncology会议摘要
  15. Conversion surgery following immuno-chemotherapy in initially-unresectable esophageal squamous cell carcinoma: A real-world multicenter study.2022Journal of Clinical Oncology会议摘要
  16. One-day preoperative systemic treatment regimen outcompetes five-day regimen in potentially resectable esophageal squamous cancer2022medRxiv预印本
  17. 190P Transcriptomic molecular subtypes of esophageal squamous cell carcinoma predicted the prognosis and efficacy of neo-adjuvant immunotherapy2021Annals of Oncology论文
  18. Analysis of DNA damage response gene signature for prognosis prediction of esophageal squamous cell carcinoma.2021Journal of Clinical Oncology会议摘要
  19. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 54 篇,占 0.4%。

牵头论文
54
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 8820212022: 9920222023: 9920232024: 131320242025: 13132025

广州有 14 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma
    分期
    II期
    开始
    2023-09
    登记号
    NCT05954897

    年龄 18 岁 至 未注明(登记的条件)

    牵头:广东省人民医院广州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫与靶向药物复发与预后影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科影像/核医学科消化/肝病科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文54
  1. Laminin β1 stimulates the Hippo-YAP1 pathway to advance the progression and lenvatinib resistance in hepatocellular carcinoma.2026International journal of biological macromolecules
  2. Mechanism of d-Glucaro-1,4-lactone enhancing the anticancer efficacy of lenvatinib via the IFN-γ-STAT3-PD-L1 signaling pathway in hepatocellular carcinoma.2026Phytomedicine : international journal of phytotherapy and phytopharmacology
  3. Liver diseases, transaminases, and hepatobiliary-pancreatic cancer risk: a cohort and Mendelian randomisation study using data from UK Biobank.2025BMJ open gastroenterology免费全文
  4. AKR1D1 suppresses liver cancer progression by promoting bile acid metabolism-mediated NK cell cytotoxicity.2025Cell metabolism
  5. DTX2 attenuates Lenvatinib-induced ferroptosis by suppressing docosahexaenoic acid biosynthesis through HSD17B4-dependent peroxisomal β-oxidation in hepatocellular carcinoma.2025Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  6. Development and validation of interpretable machine learning model for pre-treatment predicting the response to targeted and immune therapy in hepatocellular carcinoma.2025European journal of radiology
  7. Comprehensive analysis of publications concerning combinations of immunotherapy and targeted therapies for hepatocellular carcinoma: a bibliometric study.2025Frontiers in immunology免费全文
  8. Anti-Hepatocellular Carcinoma Effect of Jianpi Huayu Formula: Revealing the Molecular Mechanisms of the CXCR4 - Smad2/3 Pathway in Regulating Vasculogenic Mimicry Formation and Epithelial-Mesenchymal Transition.2025Integrative cancer therapies免费全文
  9. Development of glypican-3-specific chimeric antigen receptor-modified natural killer cells and optimization as a therapy for hepatocellular carcinoma.2025Journal of leukocyte biology
  10. ENO1-BACE2-mediated LDLR cleavage promotes liver cancer progression by remodelling cholesterol metabolism.2025Journal of molecular cell biology免费全文
  11. Histidine metabolism drives liver cancer progression via immune microenvironment modulation through metabolic reprogramming.2025Journal of translational medicine免费全文
  12. TPX2 lactylation is required for the cell cycle regulation and hepatocellular carcinoma progression.2025Life science alliance免费全文
  13. Transcriptomic analysis reveals the potential role of TOE1 in hepatocellular carcinoma.2025Scientific reports免费全文
  14. Near-Infrared II Fluorescence Imaging Highlights Tumor Angiogenesis in Hepatocellular Carcinoma with a VEGFR-Targeted Probe.2025Small methods
  15. Predicting prognosis, immune landscape, and drug targets with a novel signature for hepatocellular carcinoma.2025Technology and health care : official journal of the European Society for Engineering and Medicine
  16. Impact of prior SARS-CoV-2 infection on postoperative recovery in patients with hepatocellular carcinoma resection.2024BMC gastroenterology免费全文
  17. Quercetin-induced degradation of RhoC suppresses hepatocellular carcinoma invasion and metastasis.2024Cancer medicine
  18. Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma.2024Frontiers of medicine
  19. A commentary on 'Laparoscopic anatomical versus non-anatomical hepatectomy in the treatment of hepatocellular carcinoma: a randomised controlled trial'.2024International journal of surgery (London, England)免费全文
  20. Commentary on 'Liver resection versus transarterial chemoembolisation for the treatment of intermediate hepatocellular carcinoma: a systematic review and meta-analysis'.2024International journal of surgery (London, England)免费全文
  21. Prognostic model for unresectable hepatocellular carcinoma treated with dual PD-1 and angiogenesis blockade therapy.2024Journal for immunotherapy of cancer免费全文
  22. Mechanistic insights into xanthomicrol as the active anti-HCC ingredient of Phytolacca acinosa Roxb.: A network pharmacology analysis and transcriptomics integrated experimental verification.2024Journal of ethnopharmacology
  23. Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8+ T cells in hepatocellular carcinoma.2024Journal of hepatology
  24. Adverse clinical outcomes and immunosuppressive microenvironment of RHO-GTPase activation pattern in hepatocellular carcinoma.2024Journal of translational medicine免费全文
  25. Citrullination modulation stabilizes HIF-1α to promote tumour progression.2024Nature communications免费全文
  26. HKDC1 promotes tumor immune evasion in hepatocellular carcinoma by coupling cytoskeleton to STAT1 activation and PD-L1 expression.2024Nature communications免费全文
  27. Carnosine regulation of intracellular pH homeostasis promotes lysosome-dependent tumor immunoevasion.2024Nature immunology
  28. EPDR1 promotes PD-L1 expression and tumor immune evasion by inhibiting TRIM21-dependent ubiquitylation of IkappaB kinase-β.2024The EMBO journal免费全文
  29. The genetic liability to rheumatoid arthritis may decrease hepatocellular carcinoma risk in East Asian population: a Mendelian randomization study.2023Arthritis research & therapy免费全文
  30. Identification of therapeutic targets and prognostic biomarkers among CXC chemokines in hepatocellular carcinoma microenvironment.2023Cancer biomarkers : section A of Disease markers免费全文
  31. Peripheral Th and NK cells are associated with response to lenvatinib plus PD-1 inhibitor in unresectable hepatocellular carcinoma.2023Clinical immunology (Orlando, Fla.)
  32. Characterization of heterogeneous metabolism in hepatocellular carcinoma identifies new therapeutic target and treatment strategy.2023Frontiers in immunology免费全文
  33. All-trans-retinoic acid inhibits hepatocellular carcinoma progression by targeting myeloid-derived suppressor cells and inhibiting angiogenesis.2023International immunopharmacology
  34. Molecular phenotypic linkage between N6-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  35. CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect.2023Journal of experimental & clinical cancer research : CR免费全文
  36. Itaconate promotes hepatocellular carcinoma progression by epigenetic induction of CD8+ T-cell exhaustion.2023Nature communications免费全文
  37. Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report.2023World journal of surgical oncology免费全文
  38. Albumin-Bilirubin Score to Predict Outcomes in Patients with Idiopathic Dilated Cardiomyopathy.2022Arquivos brasileiros de cardiologia免费全文
  39. Circular RNA CircITCH (has-circ-0001141) suppresses hepatocellular carcinoma (HCC) progression by sponging miR-184.2022Cell cycle (Georgetown, Tex.)免费全文
  40. Branched-chain amino acid catabolism breaks glutamine addiction to sustain hepatocellular carcinoma progression.2022Cell reports
  41. A Pyroptosis-Based Prognostic Model for Immune Microenvironment Estimation of Hepatocellular Carcinoma.2022Disease markers免费全文
  42. Preoperative prediction of intra-tumoral tertiary lymphoid structures based on CT in hepatocellular cancer.2022European journal of radiology
  43. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.2022International journal of biological sciences免费全文
  44. An injectable thermosensitive hydrogel loaded with a theranostic nanoprobe for synergistic chemo-photothermal therapy for multidrug-resistant hepatocellular carcinoma.2022Journal of materials chemistry. B
  45. Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis.2022Neoplasia (New York, N.Y.)免费全文
  46. Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literature.2022Transplantation reviews (Orlando, Fla.)
  47. Prediction of Microvascular Invasion of Hepatocellular Carcinoma Based on Preoperative Diffusion-Weighted MR Using Deep Learning.2021Academic radiology
  48. Predictive value of a novel lncRNA LINC02518 in evaluating the prognosis of patients with hepatocellular carcinoma.2021Biomarkers in medicine
  49. Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology.2021Briefings in bioinformatics
  50. HBO1 overexpression is important for hepatocellular carcinoma cell growth.2021Cell death & disease免费全文
  51. Association between hepatitis B and E virus infection and hepatocellular carcinoma risk.2021International journal of cancer
  52. Clinicopathological and prognostic value of preoperative lymphocyte to monocyte ratio for hepatocellular carcinoma following curative resection: A meta-analysis including 4,092 patients.2021Medicine免费全文
  53. DNase1L3 suppresses hepatocellular carcinoma growth via inhibiting complement autocrine effect.2021Neoplasma
  54. miR-4454 Promotes Hepatic Carcinoma Progression by Targeting Vps4A and Rab27A.2021Oxidative medicine and cellular longevity免费全文
中文论文(未计入)4
  1. Identification of prognosis-related key genes in hepatocellular carcinoma based on bioinformatics analysis.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
  2. [Research progress of radiomics in hepatocellular carcinoma].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  3. [Fontan-associated liver disease current status and transplantation consideration].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  4. [Value of radiomics model based on dynamic contrast-enhanced magnetic resonance imaging in differentiation fat-poor angiomyolipoma from alpha-fetoprotein-negative hepatocellular carcinoma in the background of non-cirrhotic liver].2022Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
  1. Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma正在招募NCT05954897牵头方II期2023-09 启动
  2. Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors状态不明NCT06182644牵头方不分期2024-01 启动
  3. Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence已完成NCT02032368牵头方不分期2010-07 启动
  4. Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients With Hepatocellular Carcinoma已完成NCT02038296牵头方III期2008-01 启动
  5. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  6. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)已完成NCT03867084研究中心III期2019-05 启动
  7. Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection已撤回NCT04044651研究中心II/III期2019-10 启动
  8. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)已完成NCT03713593研究中心III期2018-12 启动
  9. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)已完成NCT03062358研究中心III期2017-04 启动
  10. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动
  11. A Study to Evaluate SHR-1210 in Subjects With Advanced HCC已完成NCT02989922研究中心II期2016-11 启动
  12. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)已完成NCT02112656研究中心III期2014-06 启动
  13. Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma已完成NCT01210495研究中心II期2010-12 启动
  14. Urea Cream Treatment Sorafenib-Associated HSFR in HCC已完成NCT01934829研究中心II期2009-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 21 篇,占 0.2%。

牵头论文
21
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
7
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 4420232024: 6620242025: 992025

广州有 16 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 8

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
    分期
    II期
    开始
    2026-03
    登记号
    NCT07486310

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:广东省人民医院广州

  2. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  3. 正在招募
    Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
    分期
    III期
    开始
    2026-09
    登记号
    NCT07700979

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、北京、广州

  4. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

  5. 正在招募
    Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
    分期
    未注明
    开始
    2023-01
    登记号
    NCT05722275

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心北京、太原、广州、昆明、福州、郑州

  6. 正在招募
    Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    II期
    开始
    2023-11
    登记号
    NCT06155383

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心北京、厦门、哈尔滨、广州、成都、昆明、济南、福州、郑州

  7. 正在招募
    Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
    分期
    II期
    开始
    2022-01
    登记号
    NCT04840264

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学附属第六医院;另有 1 家列出的医院为研究中心广州

  8. 正在招募
    OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
    分期
    不分期
    开始
    2022-09
    登记号
    NCT05450835

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南方医科大学南方医院;另有 7 家列出的医院为研究中心广州、汕头、沈阳、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题营养与康复手术影像与人工智能
论文中的科室病理/检验科消化/肝病科影像/核医学科
牵头的论文21
  1. Multitask Deep Learning Based on Longitudinal CT Images Facilitates Prediction of Lymph Node Metastasis and Survival in Chemotherapy-Treated Gastric Cancer.2025Cancer research
  2. EGR4 transcriptionally upregulates GDF15 to promote gastric cancer metastasis.2025Cell death & disease免费全文
  3. CXCL12 expression and the survival of patients with gastric cancer: a meta-analysis.2025Clinical and experimental medicine免费全文
  4. Integrative analysis of bulk and single-cell sequencing reveals TNFSF9 as a potential regulator in microsatellite instability stomach adenocarcinoma.2025European journal of medical research免费全文
  5. Role of m7G modification regulators as biomarkers in gastric cancer subtyping and precision immunotherapy.2025International immunopharmacology
  6. LGALS9B stabilizes EEF1D protein and activates the PI3K/AKT signaling pathway to promote gastric cancer occurrence and metastasis.2025Oncogene
  7. Diagnostic challenges of rarely well-differentiated adenocarcinoma of the stomach.2025Pathology oncology research : POR免费全文
  8. Single-cell RNA sequencing analysis revealed the immunosuppressive remodeling of tumor-associated macrophages mediated by the MIF-CD74 axis in gastric cancer.2025Scientific reports免费全文
  9. Hepatic Portal Venous Gas and Pneumatosis Intestinalis Associated With Early Oral Feeding After Laparoscopic Total Gastrectomy.2025The American surgeon
  10. KDM3A Ablation Activates Endogenous Retrovirus Expression to Stimulate Antitumor Immunity in Gastric Cancer.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  11. Identification of chronic non-atrophic gastritis and intestinal metaplasia stages in the Correa's cascade through machine learning analyses of SERS spectral signature of non-invasively-collected human gastric fluid samples.2024Biosensors & bioelectronics
  12. Comparative single-cell analysis reveals heterogeneous immune landscapes in adenocarcinoma of the esophagogastric junction and gastric adenocarcinoma.2024Cell death & disease免费全文
  13. GLT8D2 is a prognostic biomarker and regulator of immune cell infiltration in gastric cancer.2024Frontiers in immunology免费全文
  14. The prognostic implications and tumor-promoting functions of CHSY3 in gastric cancer.2024Frontiers in immunology免费全文
  15. m6A modification enhances the stability of CDC25A promotes tumorigenicity of esophagogastric junction adenocarcinoma via cell cycle.2024International journal of biological sciences免费全文
  16. Prognostic value of a new staging system for adenocarcinoma of the esophagogastric junction after preoperative radiation therapy.2023Asian journal of surgery
  17. Lymph node evaluation after neoadjuvant therapy for patients with adenocarcinoma of the esophagogastric junction.2023Asian journal of surgery
  18. Clinical characteristics and prognostic outcomes for adenocarcinoma of esophagogastric junction in early-onset patients: a population-based appraisal.2023Journal of cancer research and clinical oncology免费全文
  19. Profiling of the genetic features of Chinese patients with gastric cancer with HRD germline mutations in a large-scale retrospective study.2023Journal of medical genetics免费全文
  20. Evaluation of proton pump inhibitors and risks of gastric cancer.2022Gut
  21. The ratio of serum C-reactive protein level on postoperative day 3 to day 2 is a good marker to predict postoperative complications after laparoscopic radical gastrectomy for gastric cancer.2022Langenbeck's archives of surgeryRCT免费全文
中文论文(未计入)3
  1. [High expression of CREM is associated with poor prognosis in gastric cancer patients].2024Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  2. [Application of laparoscopic and open gastrectomy in enhanced recovery after surgery for gastric cancer: analysis of data from multiple centers in China].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  3. [Expression of nicotinamide-N-methyltransferase in gastric cancer and its biological and clinicopathological significance].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)31
  1. Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial即将招募NCT07486310牵头方II期2026-03 启动
  2. A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma进行中,不再招募NCT07257575牵头方II期2025-01 启动
  3. Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors状态不明NCT06182644牵头方不分期2024-01 启动
  4. Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric Cancer状态不明NCT03255811牵头方(推断)不分期2017-03 启动
  5. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  6. Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma正在招募NCT07700979研究中心III期2026-09 启动
  7. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  8. Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT06155383研究中心II期2023-11 启动
  9. Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics正在招募NCT05722275研究中心2023-01 启动
  10. OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method正在招募NCT05450835研究中心不分期2022-09 启动
  11. Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction正在招募NCT04840264研究中心II期2022-01 启动
  12. A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors已完成NCT06549816研究中心I期2024-08 启动
  13. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  14. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  15. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  16. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  17. Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab已完成NCT04276493研究中心I/II期2020-03 启动
  18. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  19. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  20. Acupuncture for QoL and Symptoms in Gastric Cancer During Adjuvant Chemotherapy已完成NCT04360577研究中心不分期2020-05 启动
  21. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis状态不明NCT04440605研究中心2020-07 启动
  22. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)已完成NCT03675737研究中心III期2018-11 启动
  23. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers状态不明NCT03468712研究中心不分期2018-03 启动
  24. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)已完成NCT03615326研究中心III期2018-10 启动
  25. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension已撤回NCT04859582研究中心III期2018-11 启动
  26. Incidence of Pancreatic Fistula After Radical Gastrectomy状态不明NCT03391687研究中心2017-12 启动
  27. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer已完成NCT02898077研究中心III期2017-03 启动
  28. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer状态不明NCT02845986研究中心II期2016-09 启动
  29. Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis状态不明NCT03023436研究中心III期2016-01 启动
  30. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2状态不明NCT02356276研究中心III期2015-05 启动
  31. Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery状态不明NCT02130752研究中心不分期2014-10 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

广州有 8 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

广州有 8 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

广州有 4 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.5%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 3320232024: 2220242025: 442025

广州有 33 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

这些论文过半是实验室或动物研究。

牵头的论文11
  1. Implant derived high local concentration of magnesium inhibits tumorigenicity of osteosarcoma.2025Biomaterials
  2. Microwave-triggered organic sensitizer for synergistic dynamic/thermal therapy of osteosarcoma.2025Biomaterials science
  3. AZIN1-dependent polyamine synthesis accelerates tumor cell cycle progression and impairs effector T-cell function in osteosarcoma.2025Cell death & disease
  4. Personalized prediction of chemotherapy efficacy in osteosarcoma through patient-derived organoids: correlation with survival and tumor proliferation potential.2025Journal of experimental & clinical cancer research : CR
  5. Dual Factor-Loaded Artificial Periosteum Accelerates Bone Regeneration.2024ACS biomaterials science & engineering
  6. Establishment of orthotopic osteosarcoma animal models in immunocompetent rats through muti-rounds of in-vivo selection.2024BMC cancer
  7. Molecular Mechanism Underlying the Action of a Celastrol-Loaded Layered Double Hydroxide-Coated Magnesium Alloy in Osteosarcoma Inhibition and Bone Regeneration.2023ACS biomaterials science & engineering
  8. Multifunctional 3D-printed scaffolds eradiate orthotopic osteosarcoma and promote osteogenesis via microwave thermo-chemotherapy combined with immunotherapy.2023Biomaterials
  9. Biodegradable photothermal thermosensitive hydrogels treat osteosarcoma by reprogramming macrophages.2023Biomaterials science
  10. Nitrogen-containing bisphosphonate-loaded micro-arc oxidation coating for biodegradable magnesium alloy pellets inhibits osteosarcoma through targeting of the mevalonate pathway.2021Acta biomaterialia
  11. Pharmacological Inhibition of Core Regulatory Circuitry Liquid-liquid Phase Separation Suppresses Metastasis and Chemoresistance in Osteosarcoma.2021Advanced science (Weinheim, Baden-Wurttemberg, Germany)
早期论文(2016–2020 年)1
  1. LncRNA FTX inhibition restrains osteosarcoma proliferation and migration via modulating miR-320a/TXNRD1.2020Cancer biology & therapy
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma状态不明NCT06412458研究中心I期2024-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

广州有 13 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of HQP1351 in Patients With GIST or Other Solid Tumors
    分期
    I期
    开始
    2018-07
    登记号
    NCT03594422

    年龄 12 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、广州、武汉、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年没有牵头神经母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 23 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)2
  1. [Effect of hot water extract of Korean ginseng on neuroblastoma cell parthanatos].2020Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  2. Adrenal neuroblastoma in an elderly adult: a case report and review of the literature.2019Journal of medical case reports

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.2%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

广州有 14 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  2. 正在招募
    A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
    分期
    I期
    开始
    2025-12
    登记号
    NCT07179679

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、南京、南充、南昌、广州、承德、苏州、西安、重庆

  3. 正在招募
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    分期
    III期
    开始
    2021-10
    登记号
    NCT05020236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题双抗与抗体药物诊断、微小残留病与危险分层肾脏与骨骼并发症
牵头的论文3
  1. The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study.2025BMC cancer免费全文
  2. Induction Chemotherapy-Related Covert Cardiac Remodeling in Pre-Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Retrospective Observational Study.2024Cancer medicine免费全文
  3. C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction.2022Journal of hematology & oncology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)20
  1. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  2. A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors正在招募NCT07179679研究中心I期2025-12 启动
  3. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments正在招募NCT05020236研究中心III期2021-10 启动
  4. A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China已完成NCT05896774研究中心I期2023-06 启动
  5. Study of 3D189 in Patients With Hematologic Malignancies已完成NCT05320809研究中心I期2022-08 启动
  6. Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma状态不明NCT05422027研究中心I/II期2022-07 启动
  7. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment进行中,不再招募NCT05455320研究中心III期2022-10 启动
  8. A Study of Daratumumab进行中,不再招募NCT05438043研究中心III期2022-12 启动
  9. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.已完成NCT05228470研究中心II期2021-12 启动
  10. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动
  11. A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma已终止NCT04735575研究中心I/II期2021-05 启动
  12. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)状态不明NCT03975907研究中心I/II期2019-06 启动
  13. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma已完成NCT03944057研究中心II期2019-09 启动
  14. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动
  15. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.进行中,不再招募NCT03539744研究中心III期2018-10 启动
  16. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  17. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动
  18. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma已完成NCT01818752研究中心III期2013-07 启动
  19. Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year已完成NCT02348528研究中心II期2012-09 启动
  20. Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma已完成NCT01593410研究中心II期2010-08 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

广州有 8 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study of YK012 in B-cell Acute Lymphoblastic Leukemia
    分期
    I/II期
    开始
    2024-09
    登记号
    NCT06580301

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心南昌、广州、徐州、杭州、贵阳、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题费城染色体与遗传学儿童
论文中的科室儿科
牵头的论文1
  1. HOX11 gene overexpression is associated with recurrence of acute B lymphoblastic leukaemia.2025British journal of haematology
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Study of YK012 in B-cell Acute Lymphoblastic Leukemia正在招募NCT06580301研究中心I/II期2024-09 启动
  2. A Study of Ponsegromab in People With Heart Failure已终止NCT05492500研究中心II期2022-09 启动
  3. Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)已完成NCT03476239研究中心III期2017-10 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

广州有 23 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 2220242025: 002025

广州有 9 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。

这些数字背后的记录
研究主题抗体与诊断影像视神经与视力
论文中的科室神经内科眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.2%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 222025

广州有 2 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。

这些数字背后的记录
研究主题诊断与鉴别肾脏、腹膜后与血管
论文中的科室病理/检验科肾内科影像/核医学科
牵头的论文3
  1. Comparison of clinical features between patients with and without renal involvement in IgG4-related disease.2025Clinical and experimental medicine免费全文
  2. Clinical and laboratory characteristics of IgG4-related disease involving multiple organs.2025Clinical rheumatology
  3. IgG4-related disease involving the cervical spinal cord.2024Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
PubMed 以外找到的论文(未计入)1
  1. The assessment of 18F-FDG PET/CT in IgG4-related disease: Case report and review of the literature2024Indian Journal of Ophthalmology - Case Reports论文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

广州有 8 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题胸腺与胸腺切除孕期、儿童与老人
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 6 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)进行中,不再招募NCT04161898研究中心III期2020-02 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

广州有 20 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

广州有 13 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

广州有 3 家医院列在法布雷病下全国有 85 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

广州有 7 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 8 篇,占 1.1%。

牵头论文
8
2021–2025 年
牵头试验
7
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 3320232024: 2220242025: 222025

广州有 20 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Correlation of Microbiome and Metabonomics With IgA Nephropathy
    分期
    未注明
    开始
    2020-05
    登记号
    NCT05190848

    年龄 16 岁 至 65 岁(登记的条件)

    牵头:广东省人民医院;另有 4 家列出的医院为研究中心广州

  2. 正在招募
    A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
    分期
    III期
    开始
    2025-02
    登记号
    NCT06819826

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心广州

  3. 正在招募
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    分期
    III期
    开始
    2025-07
    登记号
    NCT06963827

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、包头、北京、南京、南昌、南通、厦门、宁波、广州、成都、无锡、杭州、济南、深圳、珠海、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肾内科
牵头的论文8
  1. Effectiveness and safety of finerenone in the treatment of IgA Nephrology patients: a retrospective, real-world study.2025International urology and nephrology
  2. Lysosome-mediated aggregation of galactose-deficient IgA1 with transferrin receptor 1 links to IgA nephropathy.2025Nature communications
  3. Identification of susceptibility loci and relevant cell type for IgA nephropathy in Han Chinese by integrative genome-wide analysis.2024Frontiers of medicine
  4. The risk factor for adverse pregnancy outcomes and its impact on clinical effect in IgA nephropathy: A retrospective observational study.2024Nephrology (Carlton, Vic.)
  5. Genome-Wide Association Analysis of Protein-Coding Variants in IgA Nephropathy.2023Journal of the American Society of Nephrology : JASN
  6. Anomalous kinetics of galactose-deficient IgA incurring nephropathy revealed by cross-scale optical imaging.2023Kidney international
  7. Systematic Microbiome Dysbiosis Is Associated with IgA Nephropathy.2023Microbiology spectrum
  8. Increased proportion of follicular helper T cells is associated with B cell activation and disease severity in IgA nephropathy.2022Frontiers in immunology
中文论文(未计入)2
  1. [High serum cystatin C is an independent risk factor for poor renal prognosis in IgA nephropathy].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  2. [Current status and prospects of genetic research on IgA nephropathy].2024Zhonghua yi xue za zhi
早期论文(2016–2020 年)1
  1. M2a and M2b macrophages predominate in kidney tissues and M2 subpopulations were associated with the severity of disease of IgAN patients.2019Clinical immunology (Orlando, Fla.)
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
  1. Correlation of Microbiome and Metabonomics With IgA Nephropathy正在招募NCT05190848牵头方2020-05 启动
  2. Universal STAR-T Cell Injection in Autoimmune Kidney Diseases即将招募NCT07746453牵头方不分期2026-08 启动
  3. Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy状态不明NCT03218852牵头方IV期2016-12 启动
  4. A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy已完成NCT01538433牵头方2012-02 启动
  5. Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy状态不明NCT01758120牵头方IV期2012-12 启动
  6. An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data已完成NCT01502579牵头方2011-09 启动
  7. A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy已完成NCT00426348牵头方IV期2007-05 启动
  8. A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy正在招募NCT06963827研究中心III期2025-07 启动
  9. A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria正在招募NCT06819826研究中心III期2025-02 启动
  10. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases即将招募NCT06774664研究中心I/II期2025-01 启动
  11. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression进行中,不再招募NCT05797610研究中心III期2023-08 启动
  12. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  13. TESTING -ON Post-Trial ObservatioNal Cohort Study已完成NCT05434325研究中心2022-12 启动
  14. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)已完成NCT01560052研究中心不分期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.3%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 1120242025: 112025

广州有 9 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 8 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他相关研究

联系这家医院

出示给工作人员或司机的院名卡

广东省人民医院

Guangdong Provincial People's Hospital

广州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Guangdong General Hospital; Guangdong Academy of Medical Sciences; Guangdong Provincial People's Hospital Heyuan Hospital; Guangdong General Hospital/Guangdong Academy of Medical Sciences; Guangdong General Hospital & Guangdong Academy of Medical Sciences; Guangdong Academy of Medical Sciences/Guangdong General Hospital; Ganzhou Hospital of Guangdong Provincial People's Hospital; Guangdong General Hospital and Guangdong Academy of Medical Sciences

提出更正下载数据